(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 35.53% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.92%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Alvotech's revenue in 2026 is $573,350,000.On average, 6 Wall Street analysts forecast ALVO's revenue for 2026 to be $252,904,844,621, with the lowest ALVO revenue forecast at $204,902,686,847, and the highest ALVO revenue forecast at $283,046,024,247. On average, 6 Wall Street analysts forecast ALVO's revenue for 2027 to be $318,144,778,234, with the lowest ALVO revenue forecast at $251,013,425,616, and the highest ALVO revenue forecast at $363,638,546,718.
In 2029, ALVO is forecast to generate $469,271,337,924 in revenue, with the lowest revenue forecast at $450,886,869,838 and the highest revenue forecast at $483,293,389,854.